AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 4 - (NewsRx.com & NewsRx.net) -- While early detection and new drug therapies have contributed significantly to the battle against breast cancer, doctors continue to search for better methods to improve patients' odds of survival.
Higher-risk forms of cancer, such as locally advanced breast cancer (LABC), are often treated with chemotherapy prior to surgery in order to enhance the probability of surgical success. Predicting the effectiveness of this pre-surgery chemotherapy can spare patients exposure to ineffective treatment and save money in the long run.
Recently, a team of University of Washington researchers conducted a study to determine if 18F-FDG and 15O-water PET (positron emission tomography) can accurately predict patient response to neoadjuvant chemotherapy and disease-free survival (DFS). The study, published in the November 2003 issue of The Journal of Nuclear Medicine, used PET to monitor changes in glucose metabolism and tumor blood flow in 35 patients with LABC.
David A. Mankoff, MD, PhD, and colleagues reported that while patients with decreased ...